Table 2.
Relationship of intraoperative CTC levels to patient characteristics
| Intraop CTC |
||||
|---|---|---|---|---|
| % Increase | p Value | Mean Count | p Value | |
| Age (greater than 60 vs 60 yrs or less) | 31 vs 0 | 0.12 | 1.4 vs 0.3 | 0.08 |
| Ethnicity (white vs nonwhite) | 21 vs 17 | 0.64 | 1.1 vs 1.0 | 0.82 |
| Body mass index (greater than 30 vs 30 kg/m2 or less) | 25 vs 15 | 1.00 | 1.3 vs 0.8 | 0.36 |
| Prostate size (greater than 50 vs 50 cc or less) | 17 vs 23 | 1.00 | 1.2 vs 1.0 | 0.77 |
| Estimated blood loss (500 or greater vs less than 500 ml) | 13 vs 24 | 1.00 | 0.8 vs 1.2 | 0.52 |
| Operative time (greater than 5 vs 5 hrs or less) | 12 vs 38 | 0.28 | 0.6 vs 1.9 | 0.06 |
| Nerve sparing extent (bilat vs unilat or nonnerve sparing) | 21 vs 17 | 1.00 | 1.0 vs 1.2 | 0.82 |
| pT stage (pT3 or greater vs pT2) | 11 vs 25 | 0.62 | 0.8 vs 1.2 | 0.52 |
| Gleason score (greater than 7 vs 7 or less) | 18 vs 21 | 1.00 | 0.8 vs 1.2 | 0.53 |
| Prostate Ca vol (25% or greater vs less than 25% of gland) | 17 vs 23 | 1.00 | 0.8 vs 1.3 | 0.37 |
| Perineural invasion (yes vs no) | 25 vs 11 | 0.62 | 1.1 vs 0.9 | 0.72 |
| Detectable postop PSA (yes vs no) | 29 vs 17 | 0.60 | 1.0 vs 1.1 | 0.94 |
| Clinical stage (cT1c vs cT2) | 25 vs 0 | 0.54 | 1.2 vs 0.6 | 0.48 |
| Initial PSA detectable (yes vs no) | 17 vs 21 | 1.00 | 1.0 vs 1.0 | 0.94 |
| Postop progression (yes vs no) | 0 vs 25 | 0.54 | 1.2 vs 1.0 | 0.80 |